DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Centers for Disease Control
and Prevention (CDC)

11 April 2011

URGENT: PHARMACEUTICAL CUSTOMER NOTIFICATION – IMMEDIATE ACTION REQUIRED

LTC Todd Williams, U.S. Army
Director of Support Operations
USAMMA
693 Neiman Street
Fort Detrick Frederick, MD 21702

LTC Williams,

The CDC is in receipt of approval by the FDA to modify the phenol specification for diluent Lot# DV01C01 that had previously been requested to be placed on hold status 12 November 2010. All remaining inventory can be released from hold status and placed into active inventory.

Attached is the FDA approval letter for the lower phenol specification to 0.200 – 0.275%.

DILUENT FOR ACAM 2000™ SMALLPOX (VACCINIA) VACCINE, LIVE, 50% (v/v). Glycerin USP, 0.25% (v/v) Phenol USP in Water for Injection USP, IN 3 ML CLEAR GLASS, Expiration Date: 30 November 2012

LOT # DV01C01

Originally Manufactured by: Acambis, Inc, Cambridge, MA 02139

Current Manufacturer: Sanofi-Pasteur Biologics Co., Canton, MA 02021

Please let me know if you have any question. We appreciate your assistance in this incident.

Robert Carpenter
Quality Control Unit Lead
Division of Strategic National Stockpile
Office of Public Health Preparedness and
Emergency Response
Office: (770) 488-2528
Mobile: (404) 394-6159
dpn4@cdc.gov

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20852-1448

Our STN: BL **125158/117**

Sanofi Pasteur Biologics Co.
Attention: Joseph H. Quinn
38 Sidney Street
Cambridge, Massachusetts 02139

March 14, 2011

Dear Mr. Quinn:

We have approved your request to supplement your biologics license application for Smallpox (Vaccinia) Vaccine, Live (ACAM2000®) to change the phenol content specification for vaccine diluent stability from 0.225% v/v - 0.275% v/v to 0.200% v/v - 0.275% v/v. The current target concentration of phenol to be achieved during manufacture of the diluent will not change and will remain between 0.225% v/v - 0.275% v/v.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

Jerry P. Weir, Ph.D.
Director
Division of Viral Products
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

sanofi pasteur

The vaccines division of sanofi-aventis Group

Ms. Mary Malarkey (HFM-600)
Director, Office of Compliance and Biologics Quality
Food and Drug Administration
Center for Biologics Evaluation and Research
Woodmont Office Center, Suite 200N
1401 Rockville Pike
Rockville, MD 20852-1448

04 April 2011

RE: Reporting of Biological Product Deviation - 21 CFR 600.14
ACAM2000® Small Pox (Vaccinia) Vaccine, Live
Amendment to BPDR CY19-DIL-10302-A: Stability OOS for Preservative Content (Diluent)

Dear Ms. Malarkey:

On 29 October 2010, Sanofi Pasteur Biologics Co. (Biologics License Number 1815; FDA Registration Number 3004051669) submitted Biological Product Deviation Report CY19-DIL-10302-A reporting an Out of Specification (OOS) for Phenol Content for ACAM2000 Smallpox (Vaccinia) Vaccine, Live Diluent Lot DV01C01 at the 24 month stability time point. The phenol specification at the time of the deviation was 0.225 – 0.275% v/v. A result of 0.213% v/v was obtained for the upright orientation and a result of 0.214% v/v was obtained for the inverted orientation. Thereafter, an amendment to the BPDR was filed on 23 November 2010 due to a minor discrepancy that was discovered in the reported information. This second amendment is being submitted to provide additional information that will close out this issue.

The original BPDR recommended placing the suspect diluent lot on hold within the CDC pending the outcome of the Prior Approval Supplement (PAS) that was being assembled that proposed lowering the phenol specification from 0.225 – 0.275% v/v to 0.200 – 0.275% v/v. On 12 November 2010, the PAS (STN: 125158/117) was submitted to CBER. The recommendation to place the lot on hold was reiterated later that day during a telephone discussion held with representatives from Sanofi Pasteur, the DOD, the CDC and the Center for Biologics Evaluation and Research (CBER). In response, the CDC placed the balance of Diluent Lot DV01C01 on hold within the Strategic National Stockpile (SNS) while awaiting the outcome of the PAS.

During the PAS review period, Diluent Lot DV01E01 also tested OOS for Phenol Content at the 18 month stability time point. A result of 0.221% v/v was obtained for the upright orientation and a result of 0.221% v/v was obtained for the inverted orientation.

On 14 March 2011, CBER approved the PAS to lower the phenol specification to 0.200 – 0.275% v/v (See attached). In response, Sanofi Pasteur will communicate the approval to the CDC so the on hold designation can be removed from impacted product and normal distribution of material can resume.

Thank you for your consideration of this matter. If you have questions or comments, please contact Jonathan W. Schmidt, Deputy Director of Regulatory Affairs by telephone (570) 957-3378, facsimile (570) 957-8652 or myself by telephone (570) 957-4359, facsimile (570) 957-5529.

Sincerely,

for Joseph H. Quinn
Senior Director, Regulatory Affairs U.S.
and Authorized Official

JHQ/JWS/kjr